Table 1.
Incidence and mortality rate of P. jirovecii pneumonia in RA patients during immunosuppressive therapy in Japan
| Anti-RA agents | PCP incidence, n (%)a | Mortality, n (%)a |
|---|---|---|
| MTX | 236 | 28 (11.9) |
| Tacrolimus | 14 | 4 (28.6) |
| Infliximab | 188 (0.3) | 19 (10.1) |
| Etanercept | 81 (0.1) | 15 (18.5) |
| Adalimumab | 54 (0.3) | 10 (18.5) |
| Golimumab | 1 (0.03) | 0 |
| Tocilizumab | 14 (0.2) | 2 (14.3) |
| Abatacept | 9 (0.1) | 2 (22.2) |
aPCP incidence and mortality are expressed as numbers of patients who developed PCP during treatment with the respective immunosuppressive agents and who died due to this pneumonia, respectively. Exact numbers of patients who used MTX and tacrolimus were not available. Data were obtained from the most recent surveillance reports by individual pharmaceutical companies in Japan (S. Mori, June 2012, personal communication).